On Thursday morning 08/01/2024 the UnitedHealth Inc. share started trading at the price of $575.74.
Compared to the closing price on Wednesday 07/31/2024 on BTT of $576.16, this is a drop of 0.07%.
There are 920.39 M shares outstanding in UnitedHealth Inc., which values the company at $528.93 B.
Is UnitedHealth stock a Buy, Sell or Hold?
UnitedHealth stock has received a consensus rating of buy. The average rating score is A2 and is based on 70 buy ratings, 10 hold ratings, and 3 sell ratings.What was the 52-week low for UnitedHealth stock?
The low in the last 52 weeks of UnitedHealth stock was 436.38. According to the current price, UnitedHealth is 131.43% away from the 52-week low.What was the 52-week high for UnitedHealth stock?
The high in the last 52 weeks of UnitedHealth stock was 587.19. According to the current price, UnitedHealth is 97.68% away from the 52-week high.What are analysts forecasts for UnitedHealth stock?
The 83 analysts offering price forecasts for UnitedHealth have a median target of 587.77, with a high estimate of 680.00 and a low estimate of 460.00. The median estimate represents a 97.58 difference from the last price of 573.55.UnitedHealth Stock Snapshot
573.96
Bid
100.00
Bid Size
574.48
Ask
100.00
Ask Size
8/1/2024
Date
1:45 PM
Zeit
151,310.00
Volume
576.16
Prev. Close
575.74
Öffnen Sie
530.40 B
Market Cap in USD
920.39 M
Number of Shares
567.09
Day Low
587.19
Day High
574.18
436.38
52 Week Low
587.19
52 Week High
574.18
7.29
Dividend in USD
1.38
Dividend Yield
22.06
P/E Ratio
99.80
Free Float in %
24.12
EPS in USD
96.06
Book Value per Share in USD
30.99
Cash Flow per Share in USD
UnitedHealth News More News
Historical Prices for UnitedHealth
| Date | Öffnen Sie | Schließen Sie | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
UnitedHealth Analyst Data
Total Analysts: 83
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 460.00
Median: 587.77
Highest: 680.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
UnitedHealth Analyst Opinions
- Alle
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 07/23/24 | Cantor Fitzgerald | Maintained Buy | $591 | |||
| 07/18/24 | UBS | Maintained Buy | $680 | |||
| 07/17/24 | Argus Research Company | Maintained Buy | $600 | |||
| 07/17/24 | Barclays Capital | Maintained Buy | $604 | |||
| 07/17/24 | Cantor Fitzgerald | Maintained Buy | $591 | |||
| 07/17/24 | Wells Fargo & Co | Maintained Buy | $630 | |||
| 07/17/24 | RBC Capital Markets | Maintained Buy | $615 | |||
| 07/17/24 | Jefferies & Company Inc. | Upgraded to Buy | $647 | |||
| 07/17/24 | Baird Patrick & Co | Maintained Buy | $640 | |||
| 07/17/24 | Morgan Stanley | Maintained Buy | $615 | |||
| 07/09/24 | Cantor Fitzgerald | Maintained Buy | $591 | |||
| 06/12/24 | Cantor Fitzgerald | Maintained Buy | $591 | |||
| 05/30/24 | J.P. Morgan | Maintained Buy | $559 | |||
| 05/30/24 | Baird Patrick & Co | Maintained Buy | $597 | |||
| 04/19/24 | Deutsche Bank | Maintained Buy | $562 | |||
| 04/17/24 | RBC Capital Markets | Maintained Buy | $555 | |||
| 04/17/24 | Barclays Capital | Maintained Buy | $560 | |||
| 04/17/24 | Piper Sandler | Maintained Buy | $571 | |||
| 04/10/24 | Cantor Fitzgerald | Maintained Buy | $591 | |||
| 04/08/24 | Wells Fargo & Co | Maintained Buy | $525 | |||
| 04/05/24 | Morgan Stanley | Maintained Buy | $584 | |||
| 04/04/24 | HSBC | Upgraded to Sell | $460 | |||
| 04/04/24 | Cantor Fitzgerald | Maintained Buy | $591 | |||
| 03/07/24 | Bank of America Merrill Lynch | Maintained Buy | $675 | |||
| 03/06/24 | Barclays Capital | Maintained Buy | $551 | |||
| 02/29/24 | RBC Capital Markets | Maintained Buy | $596 | |||
| 02/08/24 | Stephens Inc. | Maintained Buy | $605 | |||
| 01/19/24 | Cantor Fitzgerald | Maintained Buy | $591 | |||
| 01/17/24 | Oppenheimer & Co. Inc. | Maintained Buy | $610 | |||
| 01/17/24 | Piper Sandler | Maintained Buy | $581 | |||
| 01/16/24 | Stephens Inc. | Maintained Buy | $605 | |||
| 01/16/24 | RBC Capital Markets | Maintained Buy | $596 | |||
| 12/18/23 | HSBC | Downgraded to Sell | $480 | |||
| 12/13/23 | Stephens Inc. | Maintained Buy | $585 | |||
| 11/30/23 | RBC Capital Markets | Maintained Buy | $596 | |||
| 11/30/23 | Stephens Inc. | Maintained Buy | $585 | |||
| 11/21/23 | Cantor Fitzgerald | Maintained Buy | $591 | |||
| 11/20/23 | Jefferies & Company Inc. | Maintained Hold | $503 | |||
| 10/23/23 | Morgan Stanley | Maintained Buy | $579 | |||
| 10/16/23 | RBC Capital Markets | Maintained Buy | $596 | |||
| 10/16/23 | Piper Sandler | Maintained Buy | $584 | |||
| 10/16/23 | UBS | Upgraded to Buy | $640 | |||
| 10/09/23 | Jefferies & Company Inc. | Maintained Hold | $531 | |||
| 09/14/23 | Cantor Fitzgerald | Maintained Buy | $591 | |||
| 09/06/23 | HSBC | Maintained Sell | $540 | |||
| 08/11/23 | Stephens Inc. | Maintained Buy | $560 | |||
| 07/19/23 | UBS | Maintained Hold | $520 | |||
| 07/18/23 | Bernstein | Upgraded to Buy | $603 | |||
| 07/17/23 | Deutsche Bank | Maintained Buy | $555 | |||
| 07/17/23 | RBC Capital Markets | Maintained Buy | $572 |
UnitedHealth Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 398,922 | 430,209 | 461,742 | 511,905 | 581,969 |
| Dividend | 7.91 | 8.88 | 9.86 | 8.00 | - |
| Dividend Yield (in %) | 1.37 % | 1.54 % | 1.71 % | 1.39 % | - |
| EPS | 27.69 | 31.15 | 35.15 | 39.91 | 46.34 |
| P/E Ratio | 20.81 | 18.50 | 16.39 | 14.44 | 12.44 |
| EBIT | 36,536 | 40,091 | 44,513 | 47,503 | 57,177 |
| EBITDA | 38,838 | 43,953 | 48,541 | 50,123 | - |
| Net Profit | 15,207 | 27,529 | 30,810 | 33,470 | 39,197 |
| Net Profit Adjusted | 25,496 | 28,268 | 31,416 | 33,213 | 40,630 |
| Pre-Tax Profit | 32,037 | 36,223 | 40,429 | 43,299 | 51,521 |
| Net Profit (Adjusted) | 26,543 | 35,420 | 39,576 | 40,071 | - |
| EPS (Non-GAAP) ex. SOE | 26.43 | 30.02 | 34.22 | - | - |
| EPS (GAAP) | 16.19 | 29.89 | 33.84 | 39.48 | 44.70 |
| Gross Income | 95,249 | 104,899 | 114,423 | - | - |
| Cash Flow from Investing | -5,201 | -17,224 | -17,206 | -15,887 | -10,555 |
| Cash Flow from Operations | 25,389 | 34,382 | 37,644 | 43,955 | 52,030 |
| Cash Flow from Financing | -5,201 | -17,224 | -17,206 | -15,887 | -10,555 |
| Cash Flow per Share | 31.56 | 36.85 | 41.65 | 45.89 | - |
| Free Cash Flow | 22,092 | 30,818 | 33,167 | 36,767 | - |
| Free Cash Flow per Share | - | - | - | - | - |
| Book Value per Share | 106.72 | 121.78 | 139.83 | 156.54 | - |
| Net Debt | 28,152 | 15,257 | 43 | -4,564 | 6,887 |
| Research & Development Exp. | - | - | - | - | - |
| Capital Expenditure | 3,548 | 3,921 | 4,143 | 4,432 | 4,069 |
| Selling, General & Admin. Exp. | 53,102 | 57,388 | 60,953 | - | - |
| Shareholder’s Equity | 99,655 | 111,451 | 125,961 | 140,867 | 173,133 |
| Total Assets | 292,110 | 310,825 | 332,970 | 372,252 | 451,012 |
|
Previous Quarter ending 06/30/24 |
Current Quarter ending 09/30/24 |
Next Quarter ending 12/31/24 |
Current Year ending 12/31/24 |
Next Year ending 12/31/25 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | 23 | 23 | 25 | 25 |
| Average Estimate | - | 7.068 USD | 6.900 USD | 27.693 USD | 31.155 USD |
| Year Ago | - | 6.308 USD | 5.904 USD | 24.118 USD | - |
| Datum veröffentlichen | - | 10/15/2024 | 1/15/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | 16 | 16 | 21 | 21 |
| Average Estimate | - | 99,232 USD | 100,989 USD | 398,922 USD | 430,209 USD |
| Year Ago | - | 91,364 USD | 93,248 USD | 367,809 USD | - |
| Datum veröffentlichen | - | 10/15/2024 | 1/15/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Verkauf | 367,809.00 | 322,343.00 | 287,597.00 | 257,141.00 | 242,155.00 | 226,247.00 | 201,159.00 |
| Change of sales in % | 14.10 | 12.08 | 11.84 | 6.19 | 7.03 | 12.47 | 8.83 |
| Gross profit on sales | - | - | - | - | - | - | - |
| Gross profit on sales change in % | - | - | - | - | - | - | - |
| Operating income | 28,545.00 | 26,616.00 | 23,970.00 | 22,405.00 | 19,685.00 | 17,344.00 | 15,209.00 |
| Operating income change in % | 7.25 | 11.04 | 6.99 | 13.82 | 13.50 | 14.04 | 17.63 |
| Income before tax | 29,112.00 | 26,343.00 | 22,310.00 | 20,742.00 | 17,981.00 | 15,944.00 | 14,023.00 |
| Income before tax change in % | 10.51 | 18.08 | 7.56 | 15.36 | 12.78 | 13.70 | 18.21 |
| Income after tax | 22,381.00 | 20,120.00 | 17,285.00 | 15,403.00 | 13,839.00 | 11,986.00 | 10,558.00 |
| Income after tax change in % | 11.24 | 16.40 | 12.22 | 11.30 | 15.46 | 13.53 | 50.46 |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 179,496.00 | 163,955.00 | 139,275.00 | 130,141.00 | 114,595.00 | 97,995.00 | 88,808.00 |
| Long-term liabilities per share | - | - | - | - | - | - | - |
| Equity | 98,919.00 | 86,347.00 | 76,479.00 | 70,539.00 | 62,162.00 | 56,227.00 | 52,022.00 |
| Equity change in % | 14.12 | 8.38 | 9.57 | 13.67 | 11.45 | 8.20 | 24.83 |
| Balance sheet total | 278,415.00 | 250,302.00 | 215,754.00 | 200,680.00 | 176,757.00 | 154,222.00 | 140,830.00 |
| Balance sheet total change in % | 11.23 | 16.01 | 7.51 | 13.53 | 14.61 | 9.51 | 12.63 |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 392.12 | 339.31 | 300.83 | 267.58 | 250.68 | 230.16 | 204.22 |
| P/E ratio (year end quote, basic EPS) | 22.06 | 25.03 | 27.77 | 21.88 | 20.52 | 20.43 | 20.57 |
| P/E ratio (year end quote, diluted EPS) | 22.06 | 25.03 | 27.77 | 21.88 | 20.52 | 20.43 | 20.57 |
| P/E ratio (year end quote) | 22.06 | 25.03 | 27.77 | 21.88 | 20.52 | 20.43 | 20.57 |
| Dividend yield in % | 1.38 | 1.21 | 1.12 | 1.38 | 1.41 | 1.38 | 1.30 |
| Equity ratio in % | 31.88 | 31.07 | 33.26 | 32.63 | 32.60 | 33.52 | 33.92 |
| Debt ratio in % | 64.47 | 65.50 | 64.55 | 64.85 | 64.83 | 63.54 | 63.06 |
UnitedHealth Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| GARCIA PAUL R | 07/17/2024 | 30.00 | n/a | n/a | Sell | No |
| McSweeney Erin | 07/17/2024 | 1,500.00 | 7,784.68 | 579.03 | Sell | No |
| ROOS THOMAS E | 07/16/2024 | 439.00 | 29,062.30 | n/a | Sell | No |
| ROOS THOMAS E | 07/16/2024 | 2,851.00 | 29,501.30 | 569.88 | Sell | No |
| FLYNN TIMOTHY PATRICK | 06/30/2024 | 190.00 | 9,989.00 | n/a | Buy | No |
| HOOPER MICHELE J | 06/30/2024 | 114.00 | 39,282.00 | n/a | Buy | No |
| MCNABB FREDERICK WILLIAM III | 06/24/2024 | 28.00 | 12,840.00 | n/a | Buy | No |
| Gil Kristen | 06/24/2024 | 3.00 | 929.00 | n/a | Buy | No |
| ROOS THOMAS E | 06/24/2024 | 17.17 | 32,321.41 | n/a | Buy | No |
| THOMPSON BRIAN R | 06/24/2024 | 44.25 | 32,636.58 | n/a | Buy | No |
| GARCIA PAUL R | 06/24/2024 | 5.00 | 1,782.00 | n/a | Buy | No |
| Cianfrocco Heather | 06/24/2024 | 41.77 | 16,850.26 | n/a | Buy | No |
| McSweeney Erin | 06/24/2024 | 25.05 | 9,284.68 | n/a | Buy | No |
| MONTGOMERY RICE VALERIE MD | 06/24/2024 | 22.00 | 5,471.00 | n/a | Buy | No |
| Zaetta Christopher R | 06/24/2024 | 28.77 | 8,040.93 | n/a | Buy | No |
| Noseworthy John H | 06/24/2024 | 22.00 | 4,979.00 | n/a | Buy | No |
| REX JOHN F | 06/24/2024 | 76.36 | 166,357.72 | n/a | Buy | No |
| FLYNN TIMOTHY PATRICK | 06/24/2024 | 36.00 | 9,799.00 | n/a | Buy | No |
| Baker Charles D. | 06/24/2024 | 2.00 | 292.00 | n/a | Buy | No |
| HEMSLEY STEPHEN J | 06/24/2024 | 28.00 | 810,567.94 | n/a | Buy | No |
| HOOPER MICHELE J | 06/24/2024 | 155.00 | 39,168.00 | n/a | Buy | No |
| WITTY ANDREW | 06/24/2024 | 110.59 | 97,029.77 | n/a | Buy | No |
| Cianfrocco Heather | 06/06/2024 | 212.04 | 16,808.49 | 490.69 | Sell | No |
| THOMPSON BRIAN R | 06/06/2024 | 259.86 | 32,592.34 | 490.69 | Sell | No |
| McSweeney Erin | 06/06/2024 | 128.11 | 9,259.63 | 490.69 | Sell | No |
UnitedHealth Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | UnitedHealth Inc. | 7.29 | 1.38 | USD |
| 2022 | UnitedHealth Inc. | 6.40 | 1.21 | USD |
| 2021 | UnitedHealth Inc. | 5.60 | 1.12 | USD |
| 2020 | UnitedHealth Inc. | 4.83 | 1.38 | USD |
| 2019 | UnitedHealth Inc. | 4.14 | 1.41 | USD |
| 2018 | UnitedHealth Inc. | 3.45 | 1.38 | USD |
| 2017 | UnitedHealth Inc. | 2.88 | 1.30 | USD |
| 2016 | UnitedHealth Inc. | 2.38 | 1.48 | USD |
| 2015 | UnitedHealth Inc. | 1.88 | 1.59 | USD |
| 2014 | UnitedHealth Inc. | 1.41 | 1.39 | USD |
| 2013 | UnitedHealth Inc. | 1.05 | 1.40 | USD |
| 2012 | UnitedHealth Inc. | 0.80 | 1.47 | USD |
| 2011 | UnitedHealth Inc. | 0.61 | 1.21 | USD |
| 2010 | UnitedHealth Inc. | 0.41 | 1.12 | USD |
| 2009 | UnitedHealth Inc. | 0.03 | 0.10 | USD |
| 2008 | UnitedHealth Inc. | 0.03 | 0.11 | USD |
| 2007 | UnitedHealth Inc. | 0.03 | 0.05 | USD |
| 2006 | UnitedHealth Inc. | 0.03 | 0.06 | USD |
| 2005 | UnitedHealth Inc. | 0.02 | 0.03 | USD |
| 2004 | UnitedHealth Inc. | 0.02 | 0.05 | USD |
| 2003 | UnitedHealth Inc. | 0.01 | 0.03 | USD |
| 2002 | UnitedHealth Inc. | 0.01 | 0.05 | USD |
| 2001 | UnitedHealth Inc. | 0.01 | 0.06 | USD |
| 2000 | UnitedHealth Inc. | 0.01 | 0.07 | USD |
| 1999 | UnitedHealth Inc. | 0.01 | 0.15 | USD |
*Yield of the Respective Date
UnitedHealth Inc. Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 7.068 USD | Q3 2024 Earnings Release | 10/15/2024 |
| Earnings Report | 6.900 USD | Q4 2024 Earnings Release | 01/15/2025 |
| Earnings Report | 7.600 USD | Q1 2025 Earnings Release | 04/22/2025 |
| Earnings Report | 7.668 USD | Q2 2025 Earnings Release | 07/16/2025 |
UnitedHealth Inc. Past Events
| Event | Actual EPS | Info | Date |
|---|
UnitedHealth Profile
UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T.
Moody’s Daily Credit Risk Score
UnitedHealth Shareholder
| Owner | in % |
|---|---|
| Freefloat | 99.80 |
| The Vanguard Group, Inc. | 9.11 |
| Vanguard Group, Inc. (Subfiler) | 8.73 |
| State Street Corp. | 4.97 |
| Vanguard Total Stock Market ETF | 3.16 |
| Capital Research & Management Co. (World Investors) | 3.08 |
| Fidelity Management & Research Co. LLC | 2.79 |
| BlackRock Fund Advisors | 2.76 |
| T Rowe Price Associates, Inc. (13F Subfiler) | 2.69 |
| Vanguard 500 Index Fund | 2.57 |
| Wellington Management Co. LLP (Wellington Breakout) | 2.46 |
| BlackRock Institutional Trust Co. NA | 2.21 |
| Geode Capital Management LLC | 2.06 |
| Capital Research & Management Co. (Global Investors) | 1.43 |
| JPMorgan Investment Management, Inc. | 1.36 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
UnitedHealth Management
| Name | Job |
|---|---|
| Stephen J. Hemsley | Chairman |
| Thomas Edward Roos | Chief Accounting Officer & Executive VP |
| Terry M. Clark | Chief Customer & Marketing Officer & Executive VP |
| Richard J. Mattera | Chief Development Officer & Senior Vice President |
| Sandeep Dadlani | Chief Digital & Technology Officer & EVP |
| Andrew Philip Witty | Chief Executive Officer & Director |
| Brian Thompson | Chief Executive Officer-UnitedHealthcare |
| Stephanie L. Fehr | Chief Human Capital Officer & EVP-UnitedHealthcare |
| Dame Vivian Hunt | Chief Innovation Officer |
| Margaret-Mary Wilson | Chief Medical Officer & Executive Vice President |
| Daniel J. Schumacher | Chief Strategy & Growth Officer |
| Patricia L. Lewis | Chief Sustainability Officer & Executive VP |
| Kristi Hummel | Chief Talent Officer |
| Kuai H. Leong | Deputy Secretary & Senior Deputy General Counsel |
| D. Ellen Wilson | Executive Vice President |
| Richard J. Migliori | Executive Vice President |
| Todd Walthall | Executive Vice President-Enterprise Growth |
| Kristen L. Gil | Independent Director |
| Charles D. Baker | Independent Director |
| Frederick William McNabb | Independent Director |
| Timothy Patrick Flynn | Independent Director |
| Valerie C. Montgomery Rice | Independent Director |
| John H. Noseworthy | Independent Director |
| Paul R. Garcia | Independent Director |
| Michele J. Hooper | Lead Independent Director |
| John Franklin Rex | President & Chief Financial Officer |
| Joy Fitzgerald | SVP, Chief Diversity, Equity & Inclusion Officer |
| Chris Zaetta | Secretary, Chief Legal Officer & Executive VP |
| Rupert Mark Boden Bondy | Senior Counsel, EVP-Governance & Compliance |
| Brett Manderfeld | Senior VP-Capital Markets Communications Area |
| Frances Jacobs | Senior Vice President-Investor Relations |
| Zack Sopcak | Senior Vice President-Investor Relations |
| Larry C. Renfro | Vice Chairman |
| Deedrea Grein | Vice President-Corporate Strategy |
| John Walthour | Vice President-Strategic Insights |